AU2021229457A1 - Therapeutic uses of macrocyclic compounds - Google Patents

Therapeutic uses of macrocyclic compounds Download PDF

Info

Publication number
AU2021229457A1
AU2021229457A1 AU2021229457A AU2021229457A AU2021229457A1 AU 2021229457 A1 AU2021229457 A1 AU 2021229457A1 AU 2021229457 A AU2021229457 A AU 2021229457A AU 2021229457 A AU2021229457 A AU 2021229457A AU 2021229457 A1 AU2021229457 A1 AU 2021229457A1
Authority
AU
Australia
Prior art keywords
cancer
carcinoma
met
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021229457A
Other languages
English (en)
Inventor
Jingrong J. Cui
Brion William Murray
Dayong Zhai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turning Point Therapeutics Inc
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of AU2021229457A1 publication Critical patent/AU2021229457A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2021229457A 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds Abandoned AU2021229457A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984159P 2020-03-02 2020-03-02
US62/984,159 2020-03-02
PCT/US2021/020255 WO2021178296A1 (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Publications (1)

Publication Number Publication Date
AU2021229457A1 true AU2021229457A1 (en) 2022-10-20

Family

ID=77613771

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021229457A Abandoned AU2021229457A1 (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Country Status (11)

Country Link
US (1) US20250262216A1 (https=)
EP (1) EP4114530A4 (https=)
JP (1) JP2023515687A (https=)
KR (1) KR20230022151A (https=)
CN (1) CN115397514A (https=)
AU (1) AU2021229457A1 (https=)
BR (1) BR112022017425A2 (https=)
CA (1) CA3174455A1 (https=)
IL (1) IL295938A (https=)
MX (1) MX2022010945A (https=)
WO (1) WO2021178296A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902417B (zh) 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
US20240132517A1 (en) * 2021-02-10 2024-04-25 Goharmony Therapeutics (Shenzhen) Co., Ltd. Macrocyclic compound, pharmaceutical composition, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
US10689400B2 (en) * 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
CN111182903A (zh) * 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
US20250262216A1 (en) 2025-08-21
IL295938A (en) 2022-10-01
CN115397514A (zh) 2022-11-25
BR112022017425A2 (pt) 2022-11-29
EP4114530A4 (en) 2024-04-17
MX2022010945A (es) 2022-10-07
CA3174455A1 (en) 2021-09-10
WO2021178296A1 (en) 2021-09-10
KR20230022151A (ko) 2023-02-14
JP2023515687A (ja) 2023-04-13
EP4114530A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
US12310968B2 (en) Chiral diaryl macrocycles and uses thereof
US9657008B2 (en) Chemical compounds
US8937095B2 (en) Anticancer compounds
EP2663303A1 (en) Anticancer therapy with dual aurora kinase / mek inhibitors
US20140018372A1 (en) Crystalline form of a indolinone derivative and its use
AU2021229457A1 (en) Therapeutic uses of macrocyclic compounds
US20230241052A1 (en) Method of inhibiting mutant c-kit
HK1214592B (en) Chemical compounds

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period